Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Belldegrun

Showing results (81-90 of 126) with videos related to

Pageof 13
Sort By:
Journal of Immunotherapy : Official Journal of the Society for Biological Therapy|October 1, 1991
Autologous tumor-specific cytotoxicity of tumor-infiltrating lymphocytes derived from human renal cell carcinomaA S Koo, C L Tso, T Shimabukuro, et al.
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|April 1, 1993
Soluble tumor necrosis factor receptor expression in patients with metastatic renal cell carcinoma treated with interleukin-2-based immunotherapyA Belldegrun, W Pierce, D Sayah, et al.
The Journal of Urology|March 1, 1991
The effects of interleukin-6 on tumor-infiltrating lymphocytes derived from human renal cell cancerT Y Lee, A S Koo, C Peyret, et al.
Gene Therapy|September 26, 2001
Chimeric PSA enhancers exhibit augmented activity in prostate cancer gene therapy vectorsL Wu, J Matherly, A Smallwood, et al.
AJR. American Journal of Roentgenology|January 1, 1985
Differentiation of malignant from benign adrenal masses: predictive indices on computed tomographyS Hussain, A Belldegrun, S E Seltzer, et al.
The Journal of Urology|March 29, 2000
Prognostic indicators for renal cell carcinoma: a multivariate analysis of 643 patients using the revised 1997 TNM staging criteriaK H Tsui, O Shvarts, R B Smith, et al.
Surgery, Gynecology & Obstetrics|September 1, 1986
Incidentally discovered mass of the adrenal glandA Belldegrun, S Hussain, S E Seltzer, et al.
Clinical Nephrology|September 1, 1988
Metabolic and renal effects of interleukin-2 immunotherapy for metastatic cancerD E Webb, H A Austin, A Belldegrun, et al.
The Journal of Urology|July 2, 1998
Positron emission tomography in urological oncologyC K Hoh, M A Seltzer, J Franklin, et al.
The Cancer Journal From Scientific American|February 11, 1998
Interleukin-2-based immunotherapy for the treatment of metastatic renal cell carcinoma: an analysis of 203 consecutively treated patientsR Figlin, B Gitlitz, J Franklin, et al.
Pageof 13

Showing results (81-90 of 126) with videos related to

Sort By:
Pageof 13
Journal of Immunotherapy : Official Journal of the Society for Biological Therapy|October 1, 1991
Autologous tumor-specific cytotoxicity of tumor-infiltrating lymphocytes derived from human renal cell carcinomaA S Koo, C L Tso, T Shimabukuro, et al.
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|April 1, 1993
Soluble tumor necrosis factor receptor expression in patients with metastatic renal cell carcinoma treated with interleukin-2-based immunotherapyA Belldegrun, W Pierce, D Sayah, et al.
The Journal of Urology|March 1, 1991
The effects of interleukin-6 on tumor-infiltrating lymphocytes derived from human renal cell cancerT Y Lee, A S Koo, C Peyret, et al.
Gene Therapy|September 26, 2001
Chimeric PSA enhancers exhibit augmented activity in prostate cancer gene therapy vectorsL Wu, J Matherly, A Smallwood, et al.
AJR. American Journal of Roentgenology|January 1, 1985
Differentiation of malignant from benign adrenal masses: predictive indices on computed tomographyS Hussain, A Belldegrun, S E Seltzer, et al.
The Journal of Urology|March 29, 2000
Prognostic indicators for renal cell carcinoma: a multivariate analysis of 643 patients using the revised 1997 TNM staging criteriaK H Tsui, O Shvarts, R B Smith, et al.
Surgery, Gynecology & Obstetrics|September 1, 1986
Incidentally discovered mass of the adrenal glandA Belldegrun, S Hussain, S E Seltzer, et al.
Clinical Nephrology|September 1, 1988
Metabolic and renal effects of interleukin-2 immunotherapy for metastatic cancerD E Webb, H A Austin, A Belldegrun, et al.
The Journal of Urology|July 2, 1998
Positron emission tomography in urological oncologyC K Hoh, M A Seltzer, J Franklin, et al.
The Cancer Journal From Scientific American|February 11, 1998
Interleukin-2-based immunotherapy for the treatment of metastatic renal cell carcinoma: an analysis of 203 consecutively treated patientsR Figlin, B Gitlitz, J Franklin, et al.
Pageof 13